These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33150998)

  • 1. In Reply.
    Gubbi S; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL; Del Rivero J
    Oncologist; 2021 Jan; 26(1):e192-e193. PubMed ID: 33150998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer-Reply.
    Pinato DJ; Newsom-Davis T; Bower M
    JAMA Oncol; 2020 Apr; 6(4):587-588. PubMed ID: 32077899
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors: More Common than We Thought.
    Salinas C; Samtani S; Burotto M
    Oncologist; 2021 Jan; 26(1):e191. PubMed ID: 33150991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitory colitis. Authors' reply.
    Pai RK; Pai RK; Schaeffer DF; Choi WT; Kumarasinghe P; Brown I; Lauwers GY
    Aliment Pharmacol Ther; 2021 Mar; 53(5):638-639. PubMed ID: 33566423
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Y. Inagaki et al.
    Abu-Sbeih H; Faleck DM; Dougan M; Wang Y
    J Clin Oncol; 2020 May; 38(15):1749-1750. PubMed ID: 32250720
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.
    Wahl RU; Leijs M; Araujo A; Rübben A
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reply.
    Wang Z; Zhao Z; Wang J
    JAMA Oncol; 2020 Jul; 6(7):1116-1117. PubMed ID: 32352479
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease - Reply.
    Kobayashi H
    Respirology; 2020 Aug; 25(8):892-893. PubMed ID: 32072738
    [No Abstract]   [Full Text] [Related]  

  • 9. A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Liu L; Xu Q; Lizaso A; Zhang Y
    Lung Cancer; 2020 Dec; 150():254-255. PubMed ID: 33153800
    [No Abstract]   [Full Text] [Related]  

  • 10. PD-1 inhibitors for urothelial cancer: combination or sequential therapy? - Authors' reply.
    Galsky MD; Grande E
    Lancet; 2021 Dec; 396(10267):1977-1978. PubMed ID: 33341140
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
    Qu J; Jiang M; Wang L; Zhao D; Qin K; Wang Y; Tao J; Zhang X
    Biomed Pharmacother; 2020 Jul; 127():109996. PubMed ID: 32388240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body mass index: Another way to predict the efficacy of immune checkpoint inhibitors?
    Zheng SY; Cui HJ
    Int Immunopharmacol; 2020 Jul; 84():106523. PubMed ID: 32320929
    [No Abstract]   [Full Text] [Related]  

  • 13. Authors reply to letter to the editor by Dr Degens et al.
    Bommart S; Pujol JL; Coffy A; Daurès JP; Roch B
    Lung Cancer; 2021 Mar; 153():185. PubMed ID: 33461818
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
    Tang H; Guan M; Sun Z; Bai CM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectious Complications of Immune Checkpoint Inhibitors.
    Abers MS; Lionakis MS
    Infect Dis Clin North Am; 2020 Jun; 34(2):235-243. PubMed ID: 32334989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
    Kurnit KC; Reid P; Moroney JW; Fleming GF
    Gynecol Oncol; 2020 Sep; 158(3):531-537. PubMed ID: 32641238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy.
    Li S; Tajiri K
    Intern Med; 2021 Feb; 60(3):325-326. PubMed ID: 32963172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.